anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a Chinese medicinal pill for dispersing stagnated liver qi for relieving pain and preventing cancer, which is prepared from the following raw materials: the invention relates to a traditional Chinese medicine composition for treating liver depression, blood nourishing, spleen strengthening, qi circulation promoting, blood circulation promoting, detoxifying, stagnation removing, qi regulating, stasis removing, hard mass softening, food retention removing, dampness resolving and spleen invigorating. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has the effects of regulating normal physiological function, dispersing stagnated liver qi, relieving qi stagnation, removing toxic substance, resolving hard mass, invigorating spleen, eliminating dampness, and preventing and treating cancer. 4. Can obviously improve the clinical symptoms and physical signs of patients, increase blood circulation of internal organs, and level yin and yang.
The invention relates to a telemedicine system by which means medical data, analyses and results are transmitted by means of information systems. The aim of the invention is therefore to create a telemedicine system which enables, in addition to a diagnosis and/or treatment, a complete and long-term care procedure for the patient. The patient is actively involved, informed and controlled or monitored, a different continuous access to specific files being granted to all participants. The telemedicine system comprises a database for the data management, with separate data areas for the medical and personal data of the patients, and for the medical services and medical applications. The data preparation and processing is carried out on at least two physically separated computer units. The database contains files for the encoding and graduated access rights for each user. The data areas each have modules which are accessible online such that patients and medical staff can obtain information from the database and input data into same. The patient data memory, emission and reception unit for patients contains at least files for a logbook, with a reminder function, automatic encoding, and transmission of the data to the database.
A conventional carcinogenesis study in mice at doses of 0.6 to 60 mg/kg/day (about 1 to 100 times the daily maximum recommended human dose on a mg/m2 basis) administered by oral gavage for up to 2 years revealed a dose-related increase in the incidence of benign ovarian stromal tumors. The incidence of combined hepatocellular adenoma and carcinoma showed a significant trend in females when the high dose group was excluded due to low survival. In a separate study, plasma AUC0-12hr levels in mice at 60 mg/kg/day were 55 times higher than the AUC0-24hr level in breast cancer patients at the recommended dose. The carcinogenicity study in rats at oral doses of 0.1 to 10 mg/kg/day (about 0.4 to 40 times the daily maximum recommended human dose on a mg/m2 basis) for up to 2 years also produced an increase in the incidence of benign ovarian stromal tumors at 10 mg/kg/day. Ovarian hyperplasia was observed in females at doses equal to or greater than 0.1 mg/kg/day. At 10 mg/kg/day, plasma AUC0-24hr levels in rats were 80 times higher than the level in breast cancer patients at the recommended dose. The benign ovarian stromal tumors observed in mice and rats were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased luteinizing hormone resulting from the decrease in circulating estrogen.

  


Letrozole was not mutagenic in in vitro tests (Ames and E.coli bacterial tests) but was observed to be a potential clastogen in in vitro assays (CHO K1 and CCL 61 Chinese hamster ovary cells). Letrozole was not clastogenic in vivo (micronucleus test in rats).

  


In a fertility and early embryonic development toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy day 6 resulted in an increase in pre-implantation loss at doses ≥ 0.03 mg/kg/day (approximately 0.1 times the maximum recommended human dose on a mg/m2 basis). In repeat-dose toxicity studies, administration of letrozole caused sexual inactivity in females and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1 and 0.03 mg/kg in mice, rats and dogs, respectively (approximately 1, 0.4 and 0.4 times the daily maximum recommended human dose on a mg/m2 basis, respectively).
The invention discloses an alprostadil lyophilized microemulsion, and a preparation method and application thereof. The alprostadil lyophilized microemulsion includes: by weight percentage, 0.001% -0.1% of alprostadil, 1.0% -10.0% of grease, 1.0% -20.0% of an emulsifier, 1.0%-20.0% of co-emulsifier, 0.3% -1.6% of a stabilizer, 50.0% -90.0% of a cryoprotectant, and 0.0005 %-0.50 % of a pH conditioning agent. The aforementioned components are prepared into a microemulsion with particle size of 10 nm-50 nm. The microemulsion is filtrated and sterilized, then lyophilized, and ultimately prepared into an injection-used alprostadil lyophilized product with high stability, small re-dissolution particle size (average particle size within 50-100 nm) and good safety. The lyophilized microemulsion is characterized in that: microemulsion drops have a small particle size; the microemulsion can successfully realize filtration and sterilization before lyophilization; the impurity content is low; the side effects are less; the lyophilized product has physical stability and good security and has no hemolysis, irritation, allergy and other toxic irritant reactions; and the storage and transportation is convenient. Before use, adding an appropriate amount of water for injection, glucose solution or physiological saline as need, the lyophilized microemulsion is hydrated, oscillated, diluted, and redissolved into the microemulsion for use of intravenous injection.
Buprenorphine HCl contains buprenorphine, a Schedule III controlled substance. As an opioid, buprenorphine HCl exposes users to the risks of addiction, abuse, and misuse.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed buprenorphine HCl. Addiction can occur at recommended doses and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing buprenorphine HCl, and reassess all patients receiving buprenorphine HCl for the development of these behaviors and conditions.

Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol addiction or abuse) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the prescribing of buprenorphine HCl for the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as buprenorphine HCl, but use in such patients necessitates intensive counseling about the risks and proper use of buprenorphine HCl along with the frequent reevaluation for signs of addiction, abuse, and misuse.

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing buprenorphine HCl. Strategies to reduce these risks include proper product storage and control practices for a C-III drug. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Provided is a monomer danshinolic acid B injection comprising water injection and freeze-dried powder injection and preparing method thereof, the danshinolic acid B injection comprises danshinolic acid B, pH regulating substance of pharmacological action, stabilizing agent, excipient, the concentration of the danshinolic acid B is as follows: the water injection is 2 mg/ml-200mg/ml or the freeze-dried powder injection is 2mg-400mg/bottle, the pH regulating substance has the adding amount when the pH value is regulated for 2. 5-6. 5, the concentration of the stabilizing agent is 0. 0001 mg/ml-0. 1 g/ml. The invention can provide a medicament capable of treating cardiovascular and cerebrovascular diseases and being safely used on clinical.
The present invention relates to a Chinese medicinal preparation for treating gastritis due to epigastralgia, gastric ulcer, indigestion, etc. The Chinese medicinal preparation is prepared from Roxburgh rose root, Urtica dentata Hand.-Mazz., tangerine peel, agrimony, Radix Cynanchi Wilfordii and sargentgloryvine stem. The preparation which has reasonable compatibility can help patients relieve and eliminate stomachache, bellyache, etc., normalize the spleen, clear the heat, promote digestion, regulate qi and reduce the turbid. Indicated by the acute toxicity test which is carried out in the basic Tongji Medical College of Huazhong University of Science and Technology, the preparation is poisonless. Proved by the pharmacodynamics test, the preparation has the functions of preventing the gastric mucosa from being damaged, abirritating stomachache and promoting intestinal movement. In addition, the preparation has obvious therapeutic effects on treating gastritis and gastric ulcer according to the clinical observation in the traditional Chinese medical hospital of Tianmen city.
Seipin is a key regulator of lipid metabolism, the deficiency of which leads to severe lipodystrophy. Hypothalamus is the pivotal center of brain that modulates appetite and energy homeostasis, where Seipin is abundantly expressed. Whether and how Seipin deficiency leads to systemic metabolic disorders via hypothalamus-involved energy metabolism dysregulation remains to be elucidated. In the present study, we demonstrated that Seipin-deficiency induced hypothalamic inflammation, reduction of anorexigenic pro-opiomelanocortin (POMC), and elevation of orexigenic agonist-related peptide (AgRP). Importantly, administration of rosiglitazone, a thiazolidinedione antidiabetic agent, rescued POMC and AgRP expression, suppressed hypothalamic inflammation, and restored energy homeostasis in Seipin knockout mice. Our findings offer crucial insights into the mechanism of Seipin deficiency-associated energy imbalance and indicates that rosiglitazone could serve as potential intervening agent towards metabolic disorders linked to Seipin.
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but \>7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.
According to current statistics, approximately 12 % of all deaths in France occur in Nursing Home, with the number over 25% in USA. With the ageing of the population, this rate is expected to dramatically increase in the next years, to reach 40% in USA in 2020. Yet, there is some evidence that palliative care is often inadequate in Nursing Home: there is a difficulty to recognize residents who might benefit palliative care and their needs, an underassessment and under-treatment of pain and other end-of-life symptoms, and frequent burdensome treatments and hospitalizations. Several programs including palliative care consult service (with outside consultant), Nursing Home-based palliative care or Nursing Home-hospice partnerships, have succeeded in delivering high-quality palliative care in Nursing Home. But, to our knowledge, no studies examined the benefit of telemedicine for palliative care in nursing home.

During a 6 month-inclusion period, residents with palliative care needs will be included in both arms. In the intervention group, Telemedicine consultations involving Nursing Home staff and the palliative and/or geriatric unit from the University Hospital, will be organized systematically at inclusion and during the follow-up if needed. In both groups, hospitalizations and emergency hospitalizations, quality of life of the resident, satisfaction of the nursing home staff and health costs will be recorded during 6 months.
OBJECTIVE: To compare the resting energy expenditure (REE) characteristics among young men with different body mass indexes (BMI).
METHODS: Thirty young men [average age was (26.93±4.16) years] were enrolled in this study. They underwent resting metabolism tests in the Department of Sports Medicine of Peking University Third Hospital from December 2017 to June 2021. The resting metabolic rate (RMR) was measured by indirect calorimetry, the body composition was measured by bioresistance antibody component analyzer. The REE characteristics were analyzed, and 11 predictive equations were used to estimate RMR and compared with the measured value. The differences were analyzed by paired t-test and intra-class correlation coefficient (ICC).
RESULTS: The RMR of the overall 30 young men was (1 960.17±463.11) kcal/d (1 kcal=4.186 8 kJ). Including (1 744.33±249.62) kcal/d in those with normal BMI, which was significantly lower than that in those who were overweight or obese [(2 104.06± 520.32) kcal/d, P < 0.01], but the weight-corrected RMR in those with normal BMI was significantly higher than that in those who were overweight or obese [(24.02±2.61) kcal/(kg·d) vs. (19.98±4.38) kcal/(kg·d), P < 0.01]. The RMR was significantly and positively correlated with body weight, adiposity, lean body mass, body surface area, and extracellular fluid in the subjects with diffe-rent BMI (all P < 0.05). The predicted values of the 11 prediction equations were not in good agreement with the measured values (all ICC < 0.75), with relatively high agreement between the predicted and measured values of the World Health Organization (WHO) equation in overweight obese young men (ICC=0.547, P < 0.01).
CONCLUSION: There were significant differences in RMR among young men with different BMI, and the RMR after weight correction should be considered for those who were overweight or obese. The consistency between the predicted values of different prediction equations and the actual measured values of RMR was relatively poor, and it is recommended to accurately measure RMR by indirect calorimetry. For overweight or obese young men, the WHO prediction equation can be considered to calculate RMR, but it is necessary to establish an RMR prediction equation applicable to different BMI populations.
Spinal manipulation is a therapeutic procedure employed by various healthcare practitioners for alleviating acute and chronic musculoskeletal complaints. This form of treatment is also delivered to enhance the performance and augment the rehabilitation of athletes. However, despite research findings alleging the strength-modulating effects of spinal manipulation alongside numerous professional athletes' positive anecdotal claims concerning its results, the physiological processes to explain its effects remain largely unexplained. Therefore, the purpose of this work was to investigate the effects of spinal manipulation in a college-aged sample population.

This study examined the effect of spinal manipulation delivered to the lumbosacral region on concentric force production of the knee extensors and flexors. A randomized, controlled, single-blind repeated measures design was utilized with 21 subjects. Isometric and isokinetic peak torques (Nm) were recorded during two separate session while subjects performed maximal voluntary contractions post-treatment of either spinal manipulation or a sham manipulation.
BACKGROUND: Long non-coding RNA (lncRNA) plays a vital role in the occurrence and development of varieties of tumors. Previous studies have shown that lncRNA GClnc1 is highly expressed in osteosarcoma (OS). However, the mechanism of lncRNA GClnc1 in osteosarcoma has not been fully elucidated. In this study, we investigated the biological roles of lncRNA GClnc1 in osteosarcoma and unveiled its underlying mechanisms.
METHODS: The expression of lncRNA GClnc1 in OS cells was detected by real-time quantitative PCR (qRT-PCR). The functional roles of lncRNA GClnc1 were examined by CCK8, trans-well, scratch wound healing assay, colony formation, and apoptosis assays in osteosarcoma cells upon silencing or overexpressing GClnc1. Western blot analysis, qRT-PCR, and RNA co-immunoprecipitation (RIP) assays were used to detect the interaction between lncRNA GClnc1 and NONO.
RESULTS: The expression of lncRNA GClnc1 was up-regulated in osteosarcoma cell lines. Knockdown of lncRNA GClnc1 suppressed the cell growth, migration, and invasion of OS cells, whereas the over-expression of GClnc1 improved the proliferation, migration, and invasion of OS cells. Mechanistically, we identified that lncRNA GClnc1 regulates the stability of NONO by blocking FBXW7-mediated ubiquitination degradation. Additionally, overexpression of NONO can reverse GClnc1 silencing exerted suppression of the cell proliferation, migration, and invasion, and vice versa.
CONCLUSIONS: Our study elucidated that lncRNA GClnc1 participates in the progression of OS by regulating the NONO signal pathway. Targeting GClnc1 provides a potential target for future clinical treatment of OS.
INTRODUCTION: Generalized anxiety disorder (GAD) is a common mental disorder that often begins in adolescence or early adulthood and is characterized by widespread and persistent anxiety. Partial sleep deprivation (PSD) is an important risk factor for GAD development and a common comorbidity. Adolescence is a period of rapid brain and nervous system development, and during this time, the occurrence of GAD can lead to neurocognitive deficits, such as impaired attention, cognitive control, and attention bias, that significantly affect cognitive function. However, relatively little research has been conducted on GAD comorbid with PSD in early adulthood compared with other psychiatric disorders. Clinical studies have demonstrated the effectiveness of acupuncture in treating GAD and sleep disorders, but the mechanism of how acupuncture modulates neurocognitive processing in patients with GAD comorbid with PSD has not been clarified.
METHODS/DESIGN: In this randomized clinical trial, a total of 56 participants diagnosed with GAD comorbid with naturally occurring PSD and 28 healthy controls (HCs) will be recruited. The participants diagnosed with GAD comorbid with PSD will be randomly assigned to either the acupuncture group or the sham acupuncture group at a 1:1 ratio. The primary outcome measure is the Hamilton Anxiety Rating Scale (HAMA). Secondary outcome measures are the Sleep Deprivation Index (SDI), the Self-Assessment Scale for Anxiety (SAS), the Epworth Sleepiness Scale (ESS), and the State-Trait Anxiety Inventory (STAI). Additionally, three psychological paradigms (the attentional network test, psychomotor vigilance test, and emotional face Go/No-go) and event-related potential (ERP) data. Healthy volunteers will not undergo acupuncture but will instead participate in baseline assessments for the scales, mental paradigms, and ERP data. Acupuncture and sham acupuncture interventions will be conducted for 30 min, three times a week, over a 2-week period. Evaluations will be performed at zero weeks (baseline), 1 week, and 2 weeks, with the data enumerator, outcome assessor, and participant blinded to the treatment assignment.
DISCUSSION: This study contributes to the exploration of the effects of acupuncture on improving anxiety symptoms and cognitive functions in individuals with comorbid GAD and PSD.
TRIAL REGISTRATION: ClinicalTrials.gov, ChiCTR2400082221. Registered March 25, 2024.
After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
The present invention discloses a radix puerariae spleen yang promoting and flesh resolving black rice cake and a production method thereof. The black rice cake is prepared from the following raw materials in parts by weight: 100-120 parts of black glutinous rice, 30-40 parts of glutinous rice, 30-40 parts of panicum miliaceum, 10-20 parts of orange powder, 10-15 parts of coconut powder, 8-10 parts of traditional Chinese medicine powder, 2-4 parts of spice powder, and 2-4 parts of sauce prepared from five kinds of flowers (Wuhua sauce). The traditional Chinese medicine powder is prepared from radix puerariae, Chinese tamarisk twigs, semen sojae praeparatum, rhizoma bletillae, fructus gardeniae, lasiosphaera seu calvatia, bat dung, caulis lonicerae, dandelions, radix gentianae macrophyllae, herba eupatorii, and fiveleaf akebia fruits. The main steps of the production method are as follows: grinding, Chinese traditional medicinal powder preparing, spice powder preparing,  preparing of the sauce prepared from five kinds of flowers (Wuhua sauce), mixing, steaming, and shaping. The radix puerariae spleen yang promoting and flesh resolving black rice cake is prepared from the purely natural raw materials. Combination of a Chinese herbal medicine formula and the rice cake is very important. The delicious rice cake is eaten by people, the physical symptoms of people can be effectively improved and the medicines are reasonable and effective in collocation. The rice cake has the efficacies of promoting spleen yang and resolving flesh, promoting eruption and stopping diarrhea, and relieving restlessness and stopping heat after being eaten for a long term.
In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.